GlassScriptPhysician profile
Dani Kruchevsky
NPI 1063123016
$2,339.94
in general payments reported to CMS, 2019-2025
15 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what 75% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.90 · 2024: $1,079 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polynovo North America LLC | $814.50 | 2024-2025 | Novosorb Btm |
| Polymedics Innovations INC. | $325.02 | 2025 | |
| Kerecis Limited | $315.72 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Smith+Nephew, INC. | $202.18 | 2024-2025 | Collagenase Santyl, Oasis, Acticoat 4" X 4" |
| Vericel Corporation | $146.39 | 2024 | Nexobrid |
| Biotissue Holdings INC. | $140.80 | 2025 | |
| Avita Medical Americas, LLC | $133.86 | 2024-2025 | Cohealyx, Recell, Permeaderm |
| Merck Sharp & Dohme LLC | $62.25 | 2024-2025 | Zerbaxa |
| La Jolla Pharmaceutical Company | $55.65 | 2024 | Giapreza, Xerava |
| Acera Surgical, INC. | $36.23 | 2024 | Restrata Wound Matrix |
| Integra Lifesciences Corporation | $24.25 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Musculoskeletal Transplant Foundation INC. | $22.90 | 2023 | |
| Medela LLC | $22.42 | 2024 | Invia Motion Endure |
| Medline Industries LP | $20.43 | 2024 | Medline, Medline Industries, INC. |
| Shionogi INC | $17.34 | 2024 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dani Kruchevsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.